Stocks · News reference
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Tonix Pharmaceuticals Holding Corp. (TNXP)
Filed: 2026-10-15 AccNo: 0001493152-26-047139 Size: 196 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events
Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights
On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") received a notice (the "Notice") from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively,
Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA
Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.). Medicare coverage now